KIONEX Drug Patent Profile
Which patents cover Kionex, and when can generic versions of Kionex launch?
Kionex is a drug marketed by Ani Pharms and is included in two NDAs.
The generic ingredient in KIONEX is sodium polystyrene sulfonate. There is one drug master file entry for this compound. Eleven suppliers are listed for this compound. Additional details are available on the sodium polystyrene sulfonate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Kionex
A generic version of KIONEX was approved as sodium polystyrene sulfonate by CMP PHARMA INC on January 19th, 1989.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for KIONEX?
- What are the global sales for KIONEX?
- What is Average Wholesale Price for KIONEX?
Summary for KIONEX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Drug Prices: | Drug price information for KIONEX |
| DailyMed Link: | KIONEX at DailyMed |
US Patents and Regulatory Information for KIONEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ani Pharms | KIONEX | sodium polystyrene sulfonate | POWDER;ORAL, RECTAL | 040029-001 | Feb 6, 1998 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Ani Pharms | KIONEX | sodium polystyrene sulfonate | SUSPENSION;ORAL, RECTAL | 040028-001 | Sep 17, 2007 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Kionex Market Dynamics and Financial Trajectory
Kionex is a legacy sodium polystyrene sulfonate product used to reduce elevated serum potassium. Its commercial profile is defined by low-cost generic competition, limited product differentiation, safety concerns, and substitution by newer potassium binders. Kionex does not have a visible standalone revenue stream in public filings, and its financial trajectory is best assessed through market structure rather than reported brand sales.
What is Kionex and how does it work?
Kionex contains sodium polystyrene sulfonate, an ion-exchange resin that exchanges sodium for potassium in the gastrointestinal tract. It is administered orally and is labeled for the treatment of hyperkalemia. The product is available as a powder or oral suspension, depending on the marketed presentation and supplier.
Sodium polystyrene sulfonate products have been used for decades. Their principal commercial advantages are low manufacturing complexity, broad physician familiarity, and low acquisition cost. Their limitations include variable gastrointestinal tolerability, sodium loading, drug-binding interactions, and delayed or inconsistent potassium reduction.
The FDA label warns about serious gastrointestinal adverse events, including colonic necrosis, particularly when sodium polystyrene sulfonate is administered with sorbitol. The product can also cause hypokalemia, hypocalcemia, gastrointestinal constipation, and clinically important interactions with other oral medicines. These restrictions reduce its attractiveness for chronic maintenance therapy. (FDA, 2017a)
What is the FDA regulatory status of Kionex?
Kionex is an older prescription sodium polystyrene sulfonate product rather than a recently approved molecular entity. Its regulatory value comes from the existing drug application and manufacturing authorization, not from modern clinical or formulation exclusivity.
The FDA has approved newer potassium binders for hyperkalemia, including Veltassa, containing patiromer, and Lokelma, containing sodium zirconium cyclosilicate. These products were developed for more predictable potassium control and chronic use. (FDA, 2015; FDA, 2018)
| Product | Active ingredient | FDA approval period | Primary commercial position |
|---|---|---|---|
| Kionex | Sodium polystyrene sulfonate | Legacy product | Low-cost potassium binder |
| Kayexalate | Sodium polystyrene sulfonate | Legacy product | Originator-associated SPS brand |
| Veltassa | Patiromer | 2015 | Chronic hyperkalemia, non-sodium exchange |
| Lokelma | Sodium zirconium cyclosilicate | 2018 | Chronic and acute-use positioning |
Kionex does not benefit from a new chemical entity exclusivity period. The active ingredient has been commercially available for many years, and competing sodium polystyrene sulfonate products have eroded pricing power.
When did Kionex lose exclusivity?
Kionex’s commercial exclusivity effectively expired through the age of the active ingredient and the availability of competing sodium polystyrene sulfonate products. There is no meaningful remaining market exclusivity comparable to a branded small-molecule product protected by active composition-of-matter patents.
The relevant commercial protections are likely to consist of:
- Product-specific FDA approval rights
- Manufacturing know-how
- Supplier relationships
- Distribution agreements
- Potential formulation or process claims, if any remain enforceable
- Brand recognition among hospitals, nephrologists, and emergency-care providers
These protections do not prevent generic competition. The practical entry barrier for sodium polystyrene sulfonate is substantially lower than for newer potassium binders.
What patents protect Kionex?
Kionex is not primarily protected by an active composition-of-matter patent estate. Sodium polystyrene sulfonate is an old active ingredient, and the core therapeutic mechanism is in the public domain.
Any remaining intellectual-property value would more likely relate to:
- Specific oral suspension formulations
- Particle-size or resin characteristics
- Manufacturing processes
- Packaging and stability
- Combination products
- Method-of-use claims
Such rights would have limited commercial impact unless they materially improved tolerability, dosing convenience, stability, or potassium-lowering performance. A standard sodium polystyrene sulfonate product has limited ability to use formulation patents to preserve premium pricing because equivalent or therapeutically substitutable products are available.
Kionex also does not have a biosimilar-risk profile. It is a chemically manufactured small-molecule drug, not a biologic. The relevant competitive threats are generic sodium polystyrene sulfonate products and branded potassium binders.
What is the Orange Book status of Kionex?
The Orange Book relevance for Kionex is limited. Legacy products may appear in FDA drug-product records without providing meaningful current exclusivity. Orange Book listing does not itself indicate that a product has active patent protection or substantial commercial defense.
For Kionex, the principal conclusions are:
- No active new chemical entity exclusivity remains.
- Any listed product patents would need to be reviewed individually for expiration and enforceability.
- Generic sodium polystyrene sulfonate competition is already established.
- Paragraph IV litigation is unlikely to be a major current value driver for the product.
Kionex therefore should be analyzed as a mature generic or legacy-branded product, not as a protected branded asset.
How strong is the Kionex patent estate?
The patent estate is weak from a commercial-defense perspective.
| Patent-estate factor | Assessment |
|---|---|
| Composition-of-matter protection | None of meaningful current value |
| New chemical entity exclusivity | Expired |
| Formulation protection | Potentially narrow and product-specific |
| Manufacturing protection | Possible process know-how, limited blocking power |
| Method-of-use protection | Limited practical value |
| Generic substitution risk | High |
| Biosimilar risk | Not applicable |
| Pricing protection | Low |
Sodium polystyrene sulfonate products compete primarily on price, availability, hospital contracting, and prescriber familiarity. A formulation patent would need to produce a clinically meaningful benefit to support durable commercial differentiation.
What is the competitive landscape for Kionex?
Kionex competes in two separate markets.
Generic potassium binders
The direct competitors are sodium polystyrene sulfonate products sold under generic names or legacy brands such as Kayexalate. These products compete through low price and formulary availability.
The market is fragmented and generally unattractive for high-margin growth. Manufacturers can enter if they meet FDA quality, equivalence, and supply requirements. The main barriers are resin sourcing, manufacturing consistency, packaging, and quality-control validation.
Newer potassium binders
Veltassa and Lokelma compete for patients who require chronic potassium control, particularly those with chronic kidney disease, heart failure, or renin-angiotensin-aldosterone system therapy.
Their commercial advantages include:
- Greater positioning for chronic management
- More modern clinical development programs
- Better physician support infrastructure
- Reduced dependence on sodium loading in the case of patiromer
- Stronger branded reimbursement strategies
- Greater ability to support premium pricing
Their disadvantages are higher acquisition cost, payer restrictions, drug-interaction management, and the need for prior authorization in some markets.
Kionex remains relevant when cost is the overriding factor or when a health system uses it as a low-cost rescue option. It is less competitive for long-term outpatient maintenance.
How do Kionex, Veltassa, and Lokelma compare?
| Attribute | Kionex | Veltassa | Lokelma |
|---|---|---|---|
| Active ingredient | Sodium polystyrene sulfonate | Patiromer | Sodium zirconium cyclosilicate |
| Product class | Legacy cation-exchange resin | Modern potassium binder | Selective inorganic potassium binder |
| Pricing | Low | Premium branded | Premium branded |
| Chronic-use positioning | Limited | Strong | Strong |
| Sodium burden | Yes | No sodium exchange mechanism | Contains sodium |
| Drug-interaction concerns | Significant | Requires separation from some medicines | Requires separation from some medicines |
| Patent defense | Weak or expired | Stronger branded estate | Stronger branded estate |
| Generic-entry risk | High | Lower before patent expiry | Lower before patent expiry |
| Main commercial advantage | Cost | Chronic treatment profile | Rapid and chronic-use positioning |
The competitive shift is from low-cost resin therapy toward products that allow physicians to maintain guideline-directed cardiovascular or kidney treatment while managing hyperkalemia.
What is the financial trajectory of Kionex?
Kionex has no publicly reported standalone revenue, operating-profit, or unit-volume history. Its commercial owner or supplier has not generally disclosed the brand as a separate reporting segment. Public company filings therefore do not support a precise Kionex revenue forecast.
The likely financial trajectory has four stages:
- Early branded commercialization supported by brand recognition and an established FDA-approved product.
- Revenue erosion from generic sodium polystyrene sulfonate competition.
- Margin compression as purchasing shifts to hospitals, wholesalers, and generic suppliers.
- Long-term stabilization at a low-revenue maintenance level, with periodic supply-driven increases rather than durable growth.
Kionex revenue exposure is likely modest relative to the portfolios of large pharmaceutical companies. The product may still generate cash flow if manufacturing and distribution costs are low, but its ability to support significant sales growth is limited.
Financial drivers
The principal positive drivers are:
- Low-cost positioning
- Persistent hyperkalemia prevalence
- Use in price-sensitive hospitals
- Limited access to newer potassium binders
- Periodic shortages of competing products
- Continued use in acute-care settings
The principal negative drivers are:
- Generic price competition
- Safety concerns involving gastrointestinal injury
- Physician preference for newer binders
- Payer substitution
- Low differentiation
- Lack of patent-supported pricing power
- Declining use for chronic therapy
What generic launch risks exist for Kionex?
Generic launch risk is already high because sodium polystyrene sulfonate has a mature competitive market. A new entrant would not need to overcome a meaningful branded patent barrier. The central risks for an incumbent supplier are price reduction, formulary displacement, and supply-chain competition.
A generic entrant would face operational rather than intellectual-property barriers:
- Demonstrating consistent resin quality
- Meeting dissolution and suspension specifications
- Managing particle-size distribution
- Controlling microbial and chemical impurities
- Establishing stable packaging
- Maintaining reliable supply of the active resin
- Satisfying FDA manufacturing inspections
These barriers can affect launch timing but are unlikely to preserve long-term pricing power.
Which companies are challenging Kionex?
The most relevant challengers are not patent litigants. They are manufacturers and marketers of generic sodium polystyrene sulfonate, along with branded developers of newer potassium binders.
Competitive pressure comes from:
- Generic sodium polystyrene sulfonate suppliers
- Kayexalate-associated products
- Veltassa and its commercial partners
- Lokelma and AstraZeneca
- Hospital-compounded or institutionally sourced alternatives where permitted
The competitive contest is primarily commercial and therapeutic. It centers on price, formulary status, safety, dosing convenience, and chronic-care outcomes rather than Paragraph IV litigation.
What patent litigation and settlement agreements affect Kionex?
No major current patent-litigation or settlement framework is central to Kionex’s value. The product’s commercial history is not driven by an active branded patent challenge comparable to newer specialty drugs.
The absence of material litigation does not indicate strong protection. It reflects the product’s age, generic status, and limited value of blocking patents. Any acquisition or licensing review should focus on FDA application status, manufacturing rights, supply agreements, product liability exposure, and regulatory compliance rather than expected patent settlements.
What manufacturing and geographic barriers affect Kionex?
Kionex has relatively low geographic exclusivity. Sodium polystyrene sulfonate products can be marketed in multiple jurisdictions under different brand names or generic labels, subject to local regulatory approvals.
The most relevant manufacturing barriers are:
- Consistent resin performance
- Control of sodium and potassium exchange capacity
- Batch-to-batch uniformity
- Oral suspension stability
- Control of gastrointestinal impurity risks
- Reliable active-pharmaceutical-ingredient sourcing
Geographic revenue is likely concentrated in markets where sodium polystyrene sulfonate remains reimbursed and where newer potassium binders face access restrictions. The United States has the clearest branded competition from Veltassa and Lokelma, while lower-income markets may retain greater dependence on older, lower-cost resins.
What is the outlook for Kionex?
Kionex is a mature, low-growth pharmaceutical product with limited patent value and high substitution risk. Its defensible market is the low-cost segment of hyperkalemia treatment, especially in hospital formularies and payer environments that restrict premium products.
The most likely outlook is stable-to-declining revenue, interrupted by temporary supply shortages, formulary changes, or shifts in access to newer potassium binders. A material financial recovery would require a new formulation, a clinically meaningful safety improvement, or a major supply disruption affecting competitors. The existing Kionex product alone does not have the commercial characteristics needed for durable premium growth.
Key Takeaways
- Kionex contains sodium polystyrene sulfonate, an old and widely available potassium binder.
- Its active ingredient has no meaningful current composition-of-matter exclusivity.
- Generic competition creates high price and substitution risk.
- Veltassa and Lokelma are the principal branded alternatives for chronic hyperkalemia.
- Kionex has no biosimilar risk because it is not a biologic.
- Public filings do not disclose standalone Kionex revenue or profit.
- The expected financial trajectory is low-growth or declining, with revenue supported by cost-sensitive and access-constrained use.
- Manufacturing quality and supply reliability matter more than patent protection.
- Patent litigation and Paragraph IV settlements are not major current value drivers.
- The product’s commercial value lies in low cost, familiarity, and availability rather than innovation or exclusivity.
FAQs
Is Kionex still commercially available?
Kionex has been marketed as a sodium polystyrene sulfonate product, but brand availability can vary by supplier, presentation, and distribution channel. Generic sodium polystyrene sulfonate remains the relevant market category.
Is Kionex cheaper than Lokelma or Veltassa?
Yes. Kionex and generic sodium polystyrene sulfonate products are generally positioned as low-cost alternatives, while Lokelma and Veltassa are branded products with substantially higher acquisition costs.
Does Kionex have FDA exclusivity?
No meaningful new-drug exclusivity remains for Kionex. Its commercial position depends on regulatory approval, manufacturing, distribution, and brand recognition.
Can Kionex be used for chronic hyperkalemia?
It can be used to reduce serum potassium, but its safety, tolerability, interaction, and sodium-burden profile limit its attractiveness for chronic maintenance therapy compared with newer binders.
Is Kionex a good pharmaceutical acquisition target?
Only as a low-cost, mature-product asset with reliable manufacturing and distribution. Its value is unlikely to come from patent protection, rapid growth, or premium pricing.
References
- U.S. Food and Drug Administration. (2015). Veltassa (patiromer) prescribing information.
- U.S. Food and Drug Administration. (2017a). Sodium polystyrene sulfonate prescribing information.
- U.S. Food and Drug Administration. (2017b). FDA Drug Safety Communication: FDA recommends separating dosing of sodium polystyrene sulfonate from other oral medications.
- U.S. Food and Drug Administration. (2018). Lokelma (sodium zirconium cyclosilicate) prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
More… ↓
